Abstract
The N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the
brain is the tripeptide molecule Glypromate® (Gly–Pro–Glu). Glypromate® has demonstrated neuroprotective effects in numerous in vitro and in vivo models of brain injury and is in clinical trials for the prevention of cognitive
impairment following cardiac surgery. NNZ-2566 is a structural analogue of Glypromate®, resulting from α-methylation of the proline moiety, which has improved the elimination
half-life and oral bioavailability over the parent peptide. In vivo, NNZ-2566 reduces injury size in rats subjected to focal stroke. An intravenous infusion
of NNZ-2566 of 4 h duration (3–10 mg/kg/h), initiated 3 h after endothelin-induced
middle-cerebral artery constriction, significantly reduced infarct area as assessed
on day 5. Neuroprotective efficacy in the MCAO model was also observed following oral
administration of the drug (30–60 mg/kg), when formulated as a microemulsion. In vitro, NNZ-2566 significantly attenuates apoptotic cell death in primary striatal cultures,
suggesting attenuation of apoptosis is one mechanism of action underlying its neuroprotective
effects. NNZ-2566 is currently in clinical trials for the treatment of cognitive deficits
following traumatic brain injury, and these data further support the development of
the drug as a neuroprotective agent for acute brain injury.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Isolation and characterization of variant IGF-1 and IGF-2 from adult human brain.FEBS Lett. 1986; 201: 46-50
- Identification of Gly–Pro–Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide.Biochem Biophys Res Commun. 1989; 165: 766-771
- Effects of IGF-1, truncated IGF-1 and the tripeptide Gly–Pro–Glu on acetylcholine release from parietal cortex of rat brain.Neuroreport. 1993; 4: 1111-1114
- Neuroprotective effects of Gly–Pro–Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro.Neuroreport. 1990; 10: 161-164
- The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity.Bioorg Med Chem Lett. 2006; 16: 3396-3400
- Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine–proline–glutamate, in the immature rat brain after hypoxic–ischemic injury.Brain Res. 2001; 922: 42-50
- Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine–proline–glutamate (GPE) following intravenous infusion in hypoxic–ischemic adult rats.Neuropharmacology. 2004; 47: 892-903
- Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia–ischemia in the neonatal rat.Dev Neurosci. 2007; 29: 393-402
- The IGF-I amino-terminal tripeptide glycine–proline–glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.Exp Neurol. 1999; 159: 84-97
- N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.Brain Res. 2000; 859: 286-292
- N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats.Neuroreport. 2004; 15: 1601-1604
- Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis.Brain. 2004; 127: 1313-1331
- Gly–Pro–Glu protects β-amyloid-induced somatostatin depletion in the rat cortex.Neuroreport. 2004; 15: 1979-1982
- Cognitive deficits following coronary artery bypass grafting: prevalence, prognosis, and therapeutic strategies.CNS Spectr. 2004; 9: 763-772
- Central nervous system injury associated with cardiac surgery.Lancet. 2006; 368: 694-703
- Pharmacokinetics of glycine–proline–glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats.Anal Biochem. 2003; 323: 156-163
- Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine–proline–glutamate in adult rat.Neuropeptides. 2005; 39: 81-87
- Synthesis and pharmacological evaluation of side chain modified glutamic acid analogues of the neuroprotective agent glycyl-L–prolyl-L–glutamic acid (GPE).Bioorg Med Chem. 2005; 13: 519-532
- Synthesis of proline-modified analogues of the neuroprotective agent glycyl-L–prolyl–glutamic acid (GPE).Tetrahedron. 2005; 61: 10018-10035
- Synthesis and pharmacological evaluation of glycine-modified analogues of the neuroprotective agent glycyl-L–prolyl-L–glutamic acid (GPE).Bioorg Med Chem. 2005; 13: 533-548
- Synthesis and neuroprotective activity of analogues of glycyl-L–prolyl-L–glutamic acid (GPE) modified at the alpha-carboxylic acid.Bioorg Med Chem. 2005; 13: 501-517
- Analogues of the neuroprotective tripeptide Gly–Pro–Glu (GPE): synthesis and structure–activity relationships.Bioorg Med Chem Lett. 2005; 15: 2279-2283
- New Gly–Pro–Glu (GPE) analogues: expedite solid-phase synthesis and biological activity.Bioorg Med Chem. 2006; 16: 1392-1396
- Synthesis of isotopically labelled glycyl-L–prolyl-L–glutamic acid (Glypromate®) and derivatives.J Label Comp Radiopharm. 2006; 49: 571-581
- Okadaic acid induces hyperphosphorylated forms of tau protein in human brain slices.Annals Neurology. 1993; 33: 77-87
- A new model of focal brain ischemia based on the intracerebral injection of endothelin-1.Ital J Neurol Sci. 1991; 12: 49-53
- Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat.J Cereb Blood Flow Metab. 1993; 13: 865-871
- A serial MR study of cerebral blood flow changes and lesion development following endothelin-1-induced ischemia in rats.Magn Reson Med. 2001; 46: 827-830
- Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats.Stroke. 1999; 30: 2701-2712
- Injury to axons and oligodendrocytes following endothelin-1-induced middle cerebral artery occlusion in conscious rats.Brain Res. 2006; 1110: 13-22
- Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats.Stroke. 2005; 36: 129-134
- Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8, and H-9.J Mol Neurosci. 1996; 7: 65-76
- The cytotoxicity and genotoxicity of okadaic acid are cell-line dependent.Toxicon. 2008; 51: 1338-1344
- Endothelin-1 induced middle cerebral artery occlusion: pathological consequences and neuroprotective effects of MK801.J Auton Nerv Syst. 1994; 49: S177-185
- Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats.Hypertension. 1992; 19: 40-46
Article info
Publication history
Published online: January 22, 2009
Accepted:
December 3,
2008
Received in revised form:
November 26,
2008
Received:
August 13,
2008
Identification
Copyright
© 2008 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
